AEON net incomeQ2 2026-$1.16M
AEON net income was -$1.16M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$6.64M a year earlier. For the full fiscal 2025 it was -$39.22M, compared with $42.01M in fiscal 2024.
AEON Biopharma Inc. (AEON) financials
For the twelve months ended Jun 30, 2026, AEON Biopharma Inc. reported -$54.62M of net income.
- Net income, TTM
- -$54.62M
- Cash
- $3.43M
- Total debt
- $1.75M
- Market cap
- $13.2M
FY2021FY2025
FY2022FY2025
AEON revenue and earnings growth
AEON EPSQ2 2026-$0.02
AEON diluted EPS was -$0.02 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$3.95.
AEON free cash flowQ4 2025-$4.71M
AEON free cash flow was -$4.71M in fiscal Q4 2025 (ended Dec 31, 2025). For the full fiscal 2025 it was -$17.31M.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Research and development | $4.09M | $14.18M | $34.75M | - |
| Selling, general and admin | $12.21M | $13.64M | $13.68M | - |
| Operating income | -$12.80M | $72.98M | -$48.43M | -$1.94M |
| Pre-tax income | -$39.22M | $42.01M | -$52.56M | $8.20M |
| Income tax | $0 | $0 | $0 | - |
| Net income | -$39.22M | $42.01M | -$52.56M | $8.20M |
| EPS, basic | -$3.95 | $77.74 | -$27.36 | - |
| EPS, diluted | -$3.95 | $72.93 | -$27.36 | - |
| Diluted shares | 9.9M | 575,945 | 1.9M | - |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Cash and equivalents | $3.01M | $13.0K | $9.75M | $5.13M |
| Current assets | $3.40M | $1.59M | $9.84M | $835.2K |
| Total assets | $5.56M | $3.14M | $10.78M | $276.95M |
| Current liabilities | $6.90M | $14.15M | $82.57M | $834.6K |
| Long-term debt | $34.60M | $11.69M | $60.43M | - |
| Total debt | $34.60M | $11.69M | $60.43M | - |
| Total liabilities | $60.59M | $31.71M | $143.24M | $17.88M |
| Shareholders' equity | -$55.03M | -$28.57M | -$270.41M | -$223.82M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Operating cash flow | -$17.31M | -$20.29M | -$35.58M | -$1.49M |
| Capital expenditures | $4.0K | - | $306.0K | - |
| Free cash flow | -$17.31M | - | -$35.89M | - |
| Investing cash flow | -$4.0K | - | -$306.0K | -$276.00M |
| Financing cash flow | $20.30M | $15.15M | $40.51M | $277.99M |
| Stock-based compensation | $5.32M | $6.25M | $5.89M | - |
| Depreciation and amortization | $78.0K | $97.0K | $68.0K | - |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $2.94M | $2.03M | $1.61M | $597.0K | $1.06M | $825.0K | $3.04M | $972.0K | $4.44M | $5.73M | - | $9.03M |
| Selling, general and admin | $2.99M | $3.90M | $3.89M | $1.93M | $3.26M | $3.13M | $2.63M | $3.04M | $3.32M | $4.65M | - | $4.95M |
| Operating income | -$5.92M | -$5.93M | -$5.51M | -$2.49M | -$4.34M | -$462.0K | -$2.32M | -$4.02M | $153.47M | -$74.15M | - | -$13.97M |
| Pre-tax income | -$1.16M | -$11.79M | -$37.14M | -$4.54M | -$6.64M | $9.10M | $2.08M | -$6.17M | $164.11M | -$118.02M | - | -$15.38M |
| Income tax | - | - | - | - | - | - | - | - | - | - | - | $91.7K |
| Net income | -$1.16M | -$11.79M | -$37.14M | -$4.54M | -$6.64M | $9.10M | $2.08M | -$6.17M | $164.11M | -$118.02M | -$27.66M | -$15.38M |
| EPS, basic | -$0.02 | -$0.29 | - | -$0.39 | -$0.60 | $2.28 | $12.85 | -$11.24 | $304.00 | -$227.87 | - | -$7.92 |
| EPS, diluted | -$0.02 | -$0.29 | - | -$0.39 | -$0.60 | $2.28 | $8.04 | -$11.24 | $304.00 | -$227.87 | - | -$7.92 |
| Diluted shares | 50.5M | 40.6M | - | 11.6M | 11.1M | 4.0M | - | 549,175 | 539,840 | 517,915 | - | 1.9M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.43M | $6.24M | $3.01M | $5.93M | $8.44M | $10.45M | $13.0K | $537.0K | $3.44M | $1.56M | $16.18M | $2.60M |
| Current assets | $3.99M | $6.63M | $3.40M | $7.41M | $10.26M | $12.32M | $1.59M | $2.37M | $4.02M | $2.50M | $16.91M | $592.1K |
| Total assets | $5.91M | $8.63M | $5.56M | $8.73M | $11.66M | $13.80M | $3.14M | $4.00M | $5.73M | $3.03M | $17.62M | $21.79M |
| Current liabilities | $7.34M | $6.67M | $6.90M | $8.23M | $9.13M | $8.64M | $14.15M | $10.73M | $10.43M | $15.96M | $14.18M | $9.46M |
| Long-term debt | $1.75M | $1.54M | $34.60M | $17.05M | $15.17M | $13.32M | $11.69M | $15.17M | $13.29M | $5.09M | - | - |
| Total debt | $1.75M | $1.54M | $34.60M | $17.05M | $15.17M | $13.32M | $11.69M | $15.17M | $13.29M | $5.09M | - | - |
| Total liabilities | $21.27M | $25.38M | $60.59M | $28.61M | $27.51M | $25.12M | $31.71M | $36.09M | $33.68M | $201.41M | $146.01M | $12.05M |
| Shareholders' equity | -$15.36M | -$16.75M | -$55.03M | -$19.87M | -$15.85M | -$11.32M | -$28.57M | -$32.09M | -$27.95M | -$198.38M | -$128.40M | -$283.89M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.70M | -$2.64M | -$4.71M | -$2.60M | -$2.09M | -$7.91M | -$621.0K | -$2.96M | -$8.12M | -$8.60M | - | -$10.09M |
| Capital expenditures | - | - | $0 | $0 | $0 | $4.0K | - | - | - | - | - | - |
| Free cash flow | - | - | -$4.71M | -$2.60M | -$2.09M | -$7.91M | - | - | - | - | - | - |
| Investing cash flow | - | - | $0 | $0 | $0 | -$4.0K | - | - | - | - | - | $80.3K |
| Financing cash flow | $886.0K | $5.87M | $1.79M | $84.0K | $84.0K | $18.35M | $97.0K | $50.0K | $10.00M | $5.00M | - | $8.00M |
| Stock-based compensation | $1.66M | $1.93M | $1.59M | $414.0K | $1.58M | $1.73M | $1.34M | $1.59M | $1.69M | $1.62M | - | $1.15M |
| Depreciation and amortization | $20.0K | $19.0K | $20.0K | $19.0K | $20.0K | $19.0K | $23.0K | $25.0K | $24.0K | $25.0K | - | $23.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 0.54 | 0.99 | 0.49 | 0.90 | 1.12 | 1.43 | 0.11 | 0.22 | 0.39 | 0.16 | 1.19 | 0.06 |
Source: XBRL data AEON Biopharma Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-72, first reported Mar 24, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
AEON peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| AEON | - | - | -$54.62M | - | $13.2M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
AEON FAQ
4 questionsIs AEON profitable?
No. AEON Biopharma Inc. reported a net loss of $54.62M for the twelve months ended Jun 30, 2026.How much cash and debt does AEON have?
AEON Biopharma Inc. reported $3.43M in cash and cash equivalents and $1.75M of debt on its most recent balance sheet in SEC filings.When did AEON last report financial results?
The latest statements here come from AEON Biopharma Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.Where does this AEON financial data come from?
Quantisnow builds these statements from the structured XBRL data AEON Biopharma Inc. files with the SEC. It is provided for information only and is not investment advice.